ERBB-2 gene overexpression and amplification in uterine sarcomas (Q35974618)

11 August 2017

ERBB-2 gene overexpression and amplification in uterine sarcomas (English)

1 reference

11 August 2017

1 reference

4

Maria Debiec-Rychter

1 reference

11 August 2017

7

Ignace Vergote

1 reference

11 August 2017

1

Frederic Amant

1 reference

11 August 2017

Veerle Vloeberghs

2

1 reference

11 August 2017

Heidi Woestenborghs

series ordinal

3

1 reference

11 August 2017

Lieve Verbist

series ordinal

5

1 reference

11 August 2017

Philippe Moerman

series ordinal

6

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

11 August 2017

1 reference

11 August 2017

95

1 reference

11 August 2017

3

1 reference

11 August 2017

583-587

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

11 August 2017

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

HER-2/neu expression: a major prognostic factor in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Different expression patterns of KIT, EGFR, and HER‐2 (c‐erbB‐2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Immunohistochemical study of c-erb B-2 expression in malignant mixed müllerian tumors of the female genital tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.041

10.1016/J.YGYNO.2004.07.041

7 January 2021

Identifiers

DOI

1 reference

11 August 2017

1 reference